High detection accuracy for atrial fibrillation detection was established among a diverse group of patients suspected of arrhythmias, heart failure and coronary artery disease. Detection reliability is key when designing remote care initiatives in larger populations.

Korhonen will lead the development of CardioSignal’s novel gyrocardiography technology to speed up its adoption across new emerging clinical applications, primarily in heart failure and aortic stenosis.

Harnessing the motion sensors of a smartphone solves critical issues in health care resourcing and timely access to specialized tests in heart failure.

How digital strategies can overcome barriers in screening heart diseases.

Patented advances in gyrocardiography bring affordable, clinical-grade disease detection to remote patients with smartphones.

CardioSignal and Mehiläinen, a well-known private provider of social and healthcare services in the Nordics, have formed a successful population health model to advance earlier detection of atrial fibrillation, a massive health care burden in the society today and a significant cause of hospitalization among older adults.